Page last updated: 2024-11-06

leucyltyrosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Leucyltyrosine, also known as Leu-Tyr, is a dipeptide composed of the amino acids leucine and tyrosine. It is a naturally occurring compound found in various proteins and has been studied for its potential biological effects.

Leu-Tyr has been investigated for its role in various biological processes, including:

* **Antioxidant activity:** Studies have shown that Leu-Tyr exhibits antioxidant properties, potentially protecting cells from damage caused by free radicals.
* **Neuroprotective effects:** Leu-Tyr has been suggested to have neuroprotective effects, potentially reducing neuronal damage in conditions like Alzheimer's disease.
* **Anti-inflammatory activity:** Research suggests that Leu-Tyr may possess anti-inflammatory properties, reducing inflammation in the body.

The synthesis of Leu-Tyr can be achieved through various methods, including:

* **Chemical synthesis:** Leu-Tyr can be synthesized chemically by coupling the amino acids leucine and tyrosine using specific reagents and conditions.
* **Enzymatic synthesis:** Enzymes like peptidases can be employed to synthesize Leu-Tyr from larger protein molecules.

Leu-Tyr is studied to understand its potential applications in:

* **Dietary supplements:** Due to its potential health benefits, Leu-Tyr is being explored as a potential ingredient in dietary supplements.
* **Therapeutic applications:** Research is underway to investigate the therapeutic potential of Leu-Tyr in treating conditions like neurodegenerative diseases and inflammatory disorders.

While research on Leu-Tyr is ongoing, further studies are required to fully elucidate its mechanisms of action, optimal dosage, and safety profile.'

leucyltyrosine: RN given refers to L-Tyr,L-Leu-isomer; RN for cpd without isomeric designation not avail 4/93 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70410
CHEMBL ID56099
CHEBI ID73591
SCHEMBL ID2474675
MeSH IDM0214058

Synonyms (26)

Synonym
leucyltyrosine
l-leucyl-l-tyrosine
968-21-8
chebi:73591 ,
CHEMBL56099 ,
L0040
h-leu-tyr-oh
bdbm50348865
AKOS010367110
n-l-leucyl-l-tyrosine
nsc 118372
einecs 213-527-8
l-y
l-leu-l-tyr
AKOS015853930
(2s)-2-[(2s)-2-amino-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoic acid
SCHEMBL2474675
(s)-2-((s)-2-amino-4-methylpentanamido)-3-(4-hydroxyphenyl)propanoic acid
mfcd00020195
AS-73052
leucyl-tyrosine
Q27141905
AMY41886
T73104
A902475
DTXSID301317217
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)44.00000.00001.612910.0000AID608775
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID1183271Inhibition of ACE (unknown origin)2014European journal of medicinal chemistry, Sep-12, Volume: 84CoMFA and CoMSIA analysis of ACE-inhibitory, antimicrobial and bitter-tasting peptides.
AID500816Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID500815Activation of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline2009Nature chemical biology, Jan, Volume: 5, Issue:1
Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor.
AID228722Bitter tasting threshold was expressed as log 1/T.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID608775Inhibition of rabbit lung ACE preincubated for 5 mins by spectrophotometric assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Angiotensin-I-converting enzyme inhibitory peptides: Chemical feature based pharmacophore generation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's3 (27.27)18.2507
2000's2 (18.18)29.6817
2010's4 (36.36)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]